Lilly announces results from lung cancer study
The Phase III POINTBREAK trial did not meet its primary…
6 September 2012 | By Eli Lilly and Company
The Phase III POINTBREAK trial did not meet its primary endpoint...
List view / Grid view
The Phase III POINTBREAK trial did not meet its primary…
6 September 2012 | By Eli Lilly and Company
The Phase III POINTBREAK trial did not meet its primary endpoint...
Overall survival data from PARAMOUNT study submitted to FDA...
4 June 2012 | By Eli Lilly and Company
Overall survival data from PARAMOUNT study submitted to FDA...
Eli Lilly and Company announced that PARAMOUNT, met its primary…
5 June 2011 | By Eli Lilly and Company
Eli Lilly and Company announced that PARAMOUNT, met its primary endpoint of progression-free survival...